ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
CD-19 항체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 8.6%를 나타낼 것으로 예측되고 26억 4,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 표적 암 치료에 대한 수요 증가, 스마트 세포 치료의 채택 확대, 혈액암 유병률 상승, 신흥 시장의 의료 접근성 확대, 차세대 면역요법 개발 및 바이오제조 기술 개선 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 항체-약물 접합체(ADC)의 발전, 이중특이성 항체 개발, 항체 설계에 AI 통합, 세포-세포 치료 플랫폼 개선, 일회용 생물반응기 채택, 나노바디 기반 치료제 등장, 생물학적 제제 제조 자동화 등이 있습니다.
향후 5년간 8.6% 성장 예측은 이 시장에 대한 이전 추정치 대비 0.4% 소폭 하향 조정된 수치입니다. 이러한 하향 조정은 주로 미국과 타국 간 관세 영향에 기인합니다. 관세 인상으로 인해 프랑스 및 영국에서 수입되는 CD19 표적 단일클론 항체 비용이 상승하여 미국 림프종 치료 센터에 부담이 가중될 전망입니다. 이는 B세포 악성종양 치료 비용을 악화시키고 면역요법 부담을 증가시킬 것입니다. 상호 보복 관세와 무역 긴장 및 제한 강화로 인한 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.
B세포 악성 종양의 증가하는 유병률은 CD19 항체 시장의 성장을 주도할 것으로 예상됩니다. B세포 악성 종양은 B세포 림프종 및 백혈병과 같이 비정상적인 B 림프구에서 기원한 암의 한 그룹을 포함하며, 이는 면역 체계에 영향을 미치고 통제되지 않은 세포 증식으로 이어진다. 이러한 악성 종양의 증가에는 인구 고령화, 유전적 소인, 환경적 노출, 생활 방식 변화, 진단 기술 발전, 면역 체계 변화 등 여러 요인이 기여합니다. CD19 항체는 악성 B 세포에 존재하는 CD19 단백질을 특이적으로 표적하여 건강한 세포는 보호하면서 효과적으로 파괴하고 면역 반응을 강화함으로써 B세포 악성 종양 치료에 핵심적인 역할을 합니다. 예를 들어, 2024년 1월 미국암협회(ACS) 보고에 따르면 미국에서 약 80,620명이 비호지킨 림프종으로 진단될 것으로 예상되며, 약 20,240명이 사망할 것으로 추정됩니다. 이처럼 B세포 악성 종양의 증가하는 발생률은 CD19 항체 시장 확장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 CD-19 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 CD-19 항체 시장 : 성장률 분석
세계의 CD-19 항체 시장 실적 : 규모와 성장(2019-2024년)
세계의 CD-19 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 CD-19 항체 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 CD-19 항체 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
B세포 비호지킨 림프종
만성 림프성 백혈병
급성 림프성 백혈병
기타 질병
세계의 CD-19 항체 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
폴리클로날
모노클로날
세계의 CD-19 항체 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
정맥내
피하
세계의 CD-19 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CD-19 항체 시장, 기타 질병 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유모세포 백혈병
발덴스트룀 거대글로불린혈증
변연 림프종
제7장 지역별, 국가별 분석
세계의 CD-19 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CD-19 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
CD-19 항체 시장 : 경쟁 구도
CD-19 항체 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Amgen Inc.
Bio-Rad Laboratories Inc.
Miltenyi Biotec GmbH
Abcam Plc
Kite Pharma Inc.
BioLegend Inc.
Xencor Inc.
Juno Therapeutics Inc.
BD Biosciences
Zenas BioPharma Inc.
Cell Signaling Technology Inc.
Santa Cruz Biotechnology Inc.
Novus Biologicals LLC
Tonbo Biosciences Inc.
Bio X Cell Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
CD-19 항체 시장(2029년) : 새로운 기회를 제공하는 국가
CD-19 항체 시장(2029년) : 새로운 기회를 제공하는 부문
CD-19 항체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
CD19 antibody is a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker primarily found on B cells. CD19 plays a crucial role in B cell development and is often overexpressed in B cell-related malignancies, including certain leukemias and lymphomas. These antibodies are widely used in immunotherapy, particularly in CAR-T cell therapy, to direct the immune system to attack CD19-expressing cancer cells.
The primary disease types in the CD19 antibody market include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and others. B-cell non-Hodgkin lymphoma originates in B lymphocytes, a type of white blood cell essential for immune defense. CD19 antibodies are classified into polyclonal and monoclonal types, with routes of administration including intravenous and subcutaneous delivery. Their applications span enzyme-linked immunosorbent assay (ELISA), flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and other diagnostic and research uses.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The CD-19 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-19 antibody market statistics, including CD-19 antibody industry global market size, regional shares, competitors with a CD-19 antibody market share, detailed CD-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-19 antibody industry. This CD-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The CD-19 antibody market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rise of immunotherapy, the increase in oncology research funding, the emergence of CAR-T cell therapies, the rise in healthcare awareness, and the expansion of personalized medicine.
The CD-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the growing demand for targeted cancer therapies, increasing adoption of smart cell therapies, rising prevalence of hematologic malignancies, expansion of healthcare access in emerging markets, and development of next-generation immunotherapies and improvement in biomanufacturing technologies. Major trends in the forecast period include advancements in antibody-drug conjugates, development of bispecific antibodies, integration of AI in antibody design, improvements in cell-cell therapy platforms, adoption of single-use bioreactors, the emergence of nanobody-based therapeutics, and automation in biologics manufacturing.
The forecast of 8.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. lymphoma treatment centers by driving up costs of CD19-targeting monoclonal antibodies imported from France and the UK, exacerbating B-cell malignancy treatment expenses and increasing immunotherapy burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of B-cell malignancies is expected to drive the growth of the CD19 antibody market. B-cell malignancies encompass a group of cancers originating from abnormal B lymphocytes, such as B-cell lymphomas and leukemias, which affect the immune system and lead to uncontrolled cell growth. Several factors contribute to the rising prevalence of these malignancies, including aging populations, genetic predisposition, environmental exposures, lifestyle changes, advancements in detection methods, and immune system alterations. CD19 antibodies play a crucial role in treating B-cell malignancies by specifically targeting the CD19 protein found on malignant B cells, effectively destroying them while sparing healthy cells and boosting the immune response. For example, in January 2024, the American Cancer Society reported that approximately 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,240 deaths. As a result, the growing incidence of B-cell malignancies is fueling the expansion of the CD19 antibody market.
Leading companies in the CD19 antibody market are focusing on technological innovations, such as genetically modified autologous T-cell immunotherapy, to improve cancer treatment effectiveness, particularly for hematologic malignancies. This therapy involves genetically engineering a patient's T cells to recognize and attack cancer cells before reintroducing them into the body to enhance immune response. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, received FDA approval for AUCATZYL (obecabtagene autoleucel) for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The treatment is designed to minimize toxicity and improve the persistence of therapeutic cells through controlled T-cell activation. It is administered as a split-dose infusion on days 1 and 10, with dosing tailored to individual patient needs based on bone marrow assessment.
In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Gracell Biotechnologies Inc. to strengthen its cell therapy pipeline. The acquisition aims to leverage Gracell Biotechnologies' innovative FasTCAR platform and expertise in developing CD19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc., a China-based clinical-stage biopharmaceutical company, focuses on discovering and developing cutting-edge cell therapies, reinforcing AstraZeneca's commitment to advancing cancer treatment options.
Major players in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.
North America was the largest region in the CD-19 antibody market in 2024. The regions covered in CD-19 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the CD-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
CD-19 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.; Amgen Inc.; Bio-Rad Laboratories Inc.; Miltenyi Biotec GmbH; Abcam Plc; Kite Pharma Inc.; BioLegend Inc.; Xencor Inc.; Juno Therapeutics Inc.; BD Biosciences; Zenas BioPharma Inc.; Cell Signaling Technology Inc.; Santa Cruz Biotechnology Inc.; Novus Biologicals LLC; Tonbo Biosciences Inc.; Bio X Cell Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. CD-19 Antibody Market Characteristics
3. CD-19 Antibody Market Trends And Strategies
4. CD-19 Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global CD-19 Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global CD-19 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global CD-19 Antibody Market Growth Rate Analysis
5.4. Global CD-19 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global CD-19 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global CD-19 Antibody Total Addressable Market (TAM)
6. CD-19 Antibody Market Segmentation
6.1. Global CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Other Disease Types
6.2. Global CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polyclonal
Monoclonal
6.3. Global CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
6.4. Global CD-19 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Linked Immunosorbent Assay
Flow Cytometry
Immunohistochemistry Frozen
Immunohistochemistry Paraffin
Other Applications
6.5. Global CD-19 Antibody Market, Sub-Segmentation Of B-Cell Non-Hodgkin Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diffuse Large B-Cell Lymphoma (DLBCL)
Follicular Lymphoma
Mantle Cell Lymphoma
6.6. Global CD-19 Antibody Market, Sub-Segmentation Of Chronic Lymphocytic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Relapsed Or Refractory CLL
Treatment-Naive CLL
6.7. Global CD-19 Antibody Market, Sub-Segmentation Of Acute Lymphoblastic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Cell Precursor ALL
Philadelphia Chromosome-Positive ALL
6.8. Global CD-19 Antibody Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hairy Cell Leukemia
Waldenstrom's Macroglobulinemia
Marginal Zone Lymphoma
7. CD-19 Antibody Market Regional And Country Analysis
7.1. Global CD-19 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global CD-19 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific CD-19 Antibody Market
8.1. Asia-Pacific CD-19 Antibody Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China CD-19 Antibody Market
9.1. China CD-19 Antibody Market Overview
9.2. China CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India CD-19 Antibody Market
10.1. India CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan CD-19 Antibody Market
11.1. Japan CD-19 Antibody Market Overview
11.2. Japan CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia CD-19 Antibody Market
12.1. Australia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia CD-19 Antibody Market
13.1. Indonesia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea CD-19 Antibody Market
14.1. South Korea CD-19 Antibody Market Overview
14.2. South Korea CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe CD-19 Antibody Market
15.1. Western Europe CD-19 Antibody Market Overview
15.2. Western Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK CD-19 Antibody Market
16.1. UK CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany CD-19 Antibody Market
17.1. Germany CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France CD-19 Antibody Market
18.1. France CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy CD-19 Antibody Market
19.1. Italy CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain CD-19 Antibody Market
20.1. Spain CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe CD-19 Antibody Market
21.1. Eastern Europe CD-19 Antibody Market Overview
21.2. Eastern Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia CD-19 Antibody Market
22.1. Russia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America CD-19 Antibody Market
23.1. North America CD-19 Antibody Market Overview
23.2. North America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA CD-19 Antibody Market
24.1. USA CD-19 Antibody Market Overview
24.2. USA CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada CD-19 Antibody Market
25.1. Canada CD-19 Antibody Market Overview
25.2. Canada CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America CD-19 Antibody Market
26.1. South America CD-19 Antibody Market Overview
26.2. South America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil CD-19 Antibody Market
27.1. Brazil CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East CD-19 Antibody Market
28.1. Middle East CD-19 Antibody Market Overview
28.2. Middle East CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa CD-19 Antibody Market
29.1. Africa CD-19 Antibody Market Overview
29.2. Africa CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. CD-19 Antibody Market Competitive Landscape And Company Profiles
30.1. CD-19 Antibody Market Competitive Landscape
30.2. CD-19 Antibody Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
31. CD-19 Antibody Market Other Major And Innovative Companies
31.1. Amgen Inc.
31.2. Bio-Rad Laboratories Inc.
31.3. Miltenyi Biotec GmbH
31.4. Abcam Plc
31.5. Kite Pharma Inc.
31.6. BioLegend Inc.
31.7. Xencor Inc.
31.8. Juno Therapeutics Inc.
31.9. BD Biosciences
31.10. Zenas BioPharma Inc.
31.11. Cell Signaling Technology Inc.
31.12. Santa Cruz Biotechnology Inc.
31.13. Novus Biologicals LLC
31.14. Tonbo Biosciences Inc.
31.15. Bio X Cell Inc.
32. Global CD-19 Antibody Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The CD-19 Antibody Market
34. Recent Developments In The CD-19 Antibody Market
35. CD-19 Antibody Market High Potential Countries, Segments and Strategies
35.1 CD-19 Antibody Market In 2029 - Countries Offering Most New Opportunities
35.2 CD-19 Antibody Market In 2029 - Segments Offering Most New Opportunities
35.3 CD-19 Antibody Market In 2029 - Growth Strategies
